Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioJet™ Oral Delivery of Hadlima® in Healthy Participants
NCT07849153Phase 1Not yet recruiting
- Sponsor
- Biora Therapeutics
- Start
- Oct 2026
- Primary completion
- Jan 2027
01
Overview
Phase 1, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA), Crohn's disease, ulcerative colitis (UC) and 1 more (3 arms), sponsored by Biora Therapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Incidence of Serious Adverse Events and 4 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)Crohn's diseaseulcerative colitis (UC)psoriasis
Beyond the preview
Go deeper on NCT07849153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07849153.